1 / 12

SHIP1 deficiency in IBD

SHIP1 deficiency in IBD. Sandra Fernandes 1 , James C. Ryan 2 , William G. Kerr 1 1 SUNY-Upstate Medical University, Syracuse, NY 2 UCSF/SFVA, San Francisco, CA Friday, December 13, 2013. DISCLOSURES. Nothing to disclose. SHIP1 and PI3K / Akt pathway. Fernandes & al., 2013.

becky
Download Presentation

SHIP1 deficiency in IBD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SHIP1 deficiency in IBD Sandra Fernandes1, James C. Ryan2, William G. Kerr1 1SUNY-Upstate Medical University, Syracuse, NY 2UCSF/SFVA, San Francisco, CA Friday, December 13, 2013

  2. DISCLOSURES • Nothing to disclose

  3. SHIP1 and PI3K/Akt pathway Fernandes& al., 2013

  4. SHIP-/- mice Germline SHIP1-deficiency cause fatal eosinophilic pneumonia and Crohn’s-like ileitis in mice For more on SHIP1 and mucosal inflammation in mouse model, please visit poster P-188 Kerr & al., GUT, 2011

  5. Study Design

  6. Western Blotting SHIP1 : P1C1 + goat anti-mouse HRP, Actin : C-19 + donkey anti-goat HRP, Santa Cruz Biotechnologies

  7. Reproducibility, Stability

  8. Protein levels vs mRNA

  9. Protein levels vs mRNA

  10. Protein degradation or translation inhibition? Modified from Grabbe & al. 2011 Ameres & Zamore, 2013

  11. Take home message • SHIP1-deficiency is found in 10/47 samples (>20% of samples) • Both CD and UC • SHIP1-deficiency is stable over months • No correlation to treatments at time of sampling or to other clinical parameters • No reduction in SHIP1 mRNA levels • Translational or post-translational

  12. Acknowledgments • William Kerr • James Ryan and his team at UCSF/SFVA • NeetuSrivastava • Raki Sudan • Bonnie Toms • Robert Brooks • Matt Gumbleton • Sonia Iyer • SudhaNeelam • Christie Youngs • Katie Miller • Scott Stegemann • Summer students • CCFA (Senior Research Award to WGK) • NIH • Paige Arnold Butterfly Run • Carol M. Baldwin Foundation

More Related